Market Cap ₹1771 Cr.
Stock P/E -5.7
P/B 1.5
Current Price ₹492
Book Value ₹ 330.1
Face Value 10
52W High ₹607
Dividend Yield 0%
52W Low ₹ 287
Solara Active Pharma Sciences Ltd manufactures, produces, strategies, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The enterprise gives APIs for a anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, nesthetics, anthelmintic, anti-arrhythmic agent, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antiepileptic, antifungal, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antigout agent, antihistamine, antihyperlipoproteinemic, antimalarial, antipsychotic, antitubercular, antitussive, antiulcerative, anxiolytic, bile acid analogue, continual alcoholism, continual kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, calcimimetic agent, cardiovascular agent, relevant frightened system agent, lipid regulating agent, loop diuretic, muscarinic agonist, neuromuscular, OAB remedy, phenylalanine reducer, healing of stroke, tardive dyskinesia, remedy of glaucoma and hyperphosphatemia, tropical anti-infective, and sort-II diabetes therapeutic classes. It also offers agreement studies and manufacturing offerings for APIs, which include contract improvement and manufacturing, analytical services, impurity synthesis, and profiling. In addition, the organisation exports its merchandise. It operates inside the Asia Pacific, Europe, North America, South America, and across the world. The employer was previously known as SSL Pharma Sciences Ltd and changed its name to Solara Active Pharma Sciences Ltd in March 2017. Solara Active Pharma Sciences Ltd was founded in 2017 and is based in Chennai, India.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 402 | 100 | 361 | 330 | 338 | 395 | 381 | 352 | 425 | 249 |
| Other Income | 3 | 5 | 6 | 7 | 4 | 7 | 5 | 2 | 1 | 0 |
| Total Income | 405 | 105 | 367 | 337 | 342 | 402 | 385 | 354 | 426 | 249 |
| Total Expenditure | 330 | 197 | 347 | 318 | 311 | 350 | 332 | 333 | 388 | 410 |
| Operating Profit | 75 | -92 | 20 | 20 | 31 | 52 | 53 | 21 | 39 | -161 |
| Interest | 17 | 18 | 21 | 23 | 22 | 24 | 22 | 25 | 24 | 25 |
| Depreciation | 28 | 28 | 28 | 28 | 29 | 28 | 26 | 26 | 26 | 26 |
| Exceptional Income / Expenses | -0 | -2 | -1 | 0 | 0 | 0 | 0 | 0 | -5 | -63 |
| Profit Before Tax | 30 | -140 | -31 | -31 | -19 | 1 | 5 | -29 | -17 | -275 |
| Provision for Tax | 0 | 0 | -33 | -15 | -9 | 0 | 1 | -10 | 0 | 0 |
| Profit After Tax | 30 | -140 | 2 | -16 | -10 | 0 | 4 | -19 | -17 | -275 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 |
| Profit After Adjustments | 30 | -140 | 2 | -16 | -10 | 0 | 4 | -20 | -17 | -275 |
| Adjusted Earnings Per Share | 8.3 | -38.9 | 0.5 | -4.6 | -2.8 | 0.1 | 1 | -5.4 | -4.8 | -76.5 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|---|
| Net Sales | 521 | 1387 | 1322 | 1617 | 1268 | 1444 | 1407 |
| Other Income | 2 | 12 | 28 | 29 | 20 | 23 | 8 |
| Total Income | 523 | 1399 | 1349 | 1646 | 1288 | 1466 | 1414 |
| Total Expenditure | 458 | 1166 | 1062 | 1231 | 1188 | 1310 | 1463 |
| Operating Profit | 65 | 233 | 287 | 415 | 100 | 156 | -48 |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 96 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 104 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -3 | 0 | -68 |
| Profit Before Tax | 6 | 68 | 115 | 222 | -91 | -45 | -316 |
| Provision for Tax | -0 | 1 | 0 | 0 | -33 | -23 | -9 |
| Profit After Tax | 6 | 67 | 115 | 221 | -58 | -22 | -307 |
| Adjustments | -6 | -8 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 60 | 115 | 221 | -58 | -22 | -308 |
| Adjusted Earnings Per Share | 0.2 | 23.1 | 42.7 | 61.6 | -16.2 | -6.2 | -85.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 14% | 3% | 23% | 0% |
| Operating Profit CAGR | 56% | -18% | 19% | 0% |
| PAT CAGR | 0% | NAN% | NAN% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 29% | -33% | 3% | NA% |
| ROE Average | -1% | 4% | 7% | 6% |
| ROCE Average | 2% | 5% | 8% | 7% |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|
| Shareholder's Funds | 764 | 956 | 1086 | 1589 | 1525 | 1500 |
| Minority's Interest | 4 | 4 | 4 | 4 | 2 | 2 |
| Borrowings | 243 | 225 | 233 | 155 | 283 | 235 |
| Other Non-Current Liabilities | 72 | 119 | 101 | 52 | 16 | -18 |
| Total Current Liabilities | 738 | 656 | 730 | 789 | 1063 | 1101 |
| Total Liabilities | 1821 | 1960 | 2153 | 2588 | 2890 | 2821 |
| Fixed Assets | 1063 | 1189 | 1368 | 1356 | 1332 | 1340 |
| Other Non-Current Assets | 150 | 123 | 113 | 174 | 319 | 293 |
| Total Current Assets | 608 | 648 | 672 | 1058 | 1239 | 1188 |
| Total Assets | 1821 | 1960 | 2153 | 2588 | 2890 | 2821 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 46 | 76 | 56 | 198 | 46 |
| Cash Flow from Operating Activities | 49 | 166 | 242 | 155 | -242 | 156 |
| Cash Flow from Investing Activities | -85 | -116 | -359 | -106 | -243 | -81 |
| Cash Flow from Financing Activities | 68 | -23 | 97 | 92 | 334 | -113 |
| Net Cash Inflow / Outflow | 31 | 27 | -20 | 142 | -151 | -38 |
| Closing Cash & Cash Equivalent | 46 | 76 | 56 | 198 | 46 | 9 |
| # | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.15 | 23.09 | 42.69 | 61.62 | -16.15 | -6.16 |
| CEPS(Rs) | 16.19 | 58.28 | 77.72 | 91.85 | 15.01 | 24.71 |
| DPS(Rs) | 0 | 5 | 2 | 7 | 0 | 0 |
| Book NAV/Share(Rs) | 309.63 | 329.64 | 366.93 | 441.06 | 423.3 | 416.43 |
| Core EBITDA Margin(%) | 11.99 | 15.92 | 19.63 | 23.87 | 6.31 | 9.27 |
| EBIT Margin(%) | 5.94 | 10.82 | 14.59 | 18.92 | -1.25 | 3.13 |
| Pre Tax Margin(%) | 1.12 | 4.88 | 8.69 | 13.7 | -7.18 | -3.1 |
| PAT Margin (%) | 1.15 | 4.84 | 8.66 | 13.69 | -4.6 | -1.54 |
| Cash Profit Margin (%) | 7.67 | 10.83 | 15.79 | 20.41 | 4.26 | 6.16 |
| ROA(%) | 0.33 | 3.55 | 5.57 | 9.34 | -2.13 | -0.78 |
| ROE(%) | 0.78 | 8.32 | 12.48 | 17.23 | -3.75 | -1.47 |
| ROCE(%) | 2.22 | 10.38 | 11.73 | 15.34 | -0.67 | 1.79 |
| Receivable days | 183.92 | 72.56 | 71.15 | 80.18 | 140.08 | 129.77 |
| Inventory Days | 131.48 | 52.85 | 68.16 | 64.87 | 125.26 | 143.29 |
| Payable days | 420.15 | 144.29 | 140.33 | 132.36 | 163.35 | 134.61 |
| PER(x) | 0 | 18.15 | 10.38 | 22.63 | 0 | 0 |
| Price/Book(x) | 0 | 1.27 | 1.21 | 3.16 | 1.57 | 0.79 |
| Dividend Yield(%) | 0 | 1.19 | 0.45 | 0.5 | 0 | 0 |
| EV/Net Sales(x) | 1.17 | 1.11 | 1.39 | 3.35 | 2.66 | 1.51 |
| EV/Core EBITDA(x) | 9.4 | 6.61 | 6.41 | 13.07 | 33.72 | 13.9 |
| Net Sales Growth(%) | 0 | 166.17 | -4.68 | 22.33 | -21.56 | 13.83 |
| EBIT Growth(%) | 0 | 384.74 | 28.46 | 58.7 | -105.17 | 385.97 |
| PAT Growth(%) | 0 | 1024.35 | 70.7 | 93.29 | -126.33 | 61.83 |
| EPS Growth(%) | 0 | 0 | 84.84 | 44.36 | -126.21 | 61.86 |
| Debt/Equity(x) | 0.83 | 0.63 | 0.72 | 0.38 | 0.67 | 0.67 |
| Current Ratio(x) | 0.82 | 0.99 | 0.92 | 1.34 | 1.17 | 1.08 |
| Quick Ratio(x) | 0.57 | 0.66 | 0.54 | 0.97 | 0.62 | 0.57 |
| Interest Cover(x) | 1.23 | 1.82 | 2.48 | 3.62 | -0.21 | 0.5 |
| Total Debt/Mcap(x) | 0 | 0.5 | 0.59 | 0.12 | 0.43 | 0.85 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 39.51 | 39.71 | 40.4 | 40.4 | 40.4 | 40.97 | 39.31 | 37.19 | 30.49 | 30.49 |
| FII | 18.15 | 19.42 | 17.93 | 18.47 | 19.26 | 19.31 | 18.71 | 17.86 | 16.62 | 15.8 |
| DII | 5.4 | 3.64 | 3.1 | 2.97 | 3.02 | 2.75 | 1.75 | 1.79 | 1.76 | 2.98 |
| Public | 36.94 | 37.22 | 38.57 | 38.16 | 37.32 | 36.96 | 40.23 | 43.16 | 51.14 | 50.74 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.42 | 1.43 | 1.45 | 1.45 | 1.45 | 1.47 | 1.41 | 1.34 | 1.1 | 1.1 |
| FII | 0.65 | 0.7 | 0.65 | 0.66 | 0.69 | 0.7 | 0.67 | 0.64 | 0.6 | 0.57 |
| DII | 0.19 | 0.13 | 0.11 | 0.11 | 0.11 | 0.1 | 0.06 | 0.06 | 0.06 | 0.11 |
| Public | 1.33 | 1.34 | 1.39 | 1.37 | 1.34 | 1.33 | 1.45 | 1.55 | 1.84 | 1.83 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3.59 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
